Skip to content

Arvinas ARVN Common Stock

Common Stock at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
500M0.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$8K+14.3%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$8K+33.3%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
150M0.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$5K+25.0%
Immunome logo
ImmunomeIMNM
$11K+22.2%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's common stock?
Arvinas (ARVN) reported common stock of $100K in Q1 2026.
How has Arvinas's common stock changed year-over-year?
Arvinas's common stock decreased by 0.0% year-over-year, from $100K to $100K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).